NLRP3 and COVID-19: Their antiviral, anti-inflammatory, antithrombotic, and antioxidant properties may benefit COVID-19 patients: (1) reduce viral load by activating autophagy and regulating SARS-CoV-2 virus degradation or replication [4]; (2) modulate the cytokine storm by blocking the NF-B pathway and NLRP3 inflammasomes [4]; (3) improve endothelial function, which contributes to COVID-19 pathogenesis [5]; (4) enhance vein thrombus resolution and reduce the risk of recurrent pulmonary embolism (PE) [5, 6].